# Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

> **NCT07572383** · PHASE2 · RECRUITING · sponsor: **Peter Caravan** · enrollment: 15 (estimated)

## Conditions studied

- Interstitial Lung Disease
- Pulmonary Fibrosis

## Interventions

- **DRUG:** [68Ga]CBP8
- **DRUG:** Gadoterate Meglumine

## Key facts

- **NCT ID:** NCT07572383
- **Lead sponsor:** Peter Caravan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07572383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07572383, "Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07572383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*